Boston Scientific ((BSX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: The Vercise DBS Registry, officially titled ‘Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry,’ aims to gather global data on the outcomes of using Boston Scientific’s Vercise DBS System for treating Parkinson’s disease. This study evaluates the effectiveness of Image Guided Programming (IGP) and the DBS Illumina 3D feature in enhancing patient treatment.
Intervention/Treatment: The study focuses on the Deep Brain Stimulation (DBS) device, specifically the Vercise DBS System, designed to alleviate symptoms of Parkinson’s disease through targeted brain stimulation.
Study Design: This observational study follows a cohort model with a prospective time perspective, meaning it observes participants over time without assigning specific interventions. The primary aim is to collect data on the real-world application of the Vercise DBS System.
Study Timeline: The study began on February 21, 2014, with the latest update submitted on October 7, 2025. These dates indicate the study’s long-term commitment to data collection and analysis, with recruitment still ongoing.
Market Implications: This update could positively influence Boston Scientific’s stock performance by reinforcing its position in the Parkinson’s treatment market. As the study progresses, investor confidence may rise due to potential advancements in treatment efficacy. Competitors in the neuromodulation space will likely monitor these developments closely.
The study is ongoing, with further details available on the ClinicalTrials portal.